Immune Pharmaceuticals, Inc. | 8-K: Current report
Immune Pharmaceuticals, Inc. | 8-K: Current report
Immune Pharmaceuticals, Inc. | S-1: General form for registration of securities under the Securities Act of 1933
Immune Pharmaceuticals, Inc. | 10-Q: Q3 2018 Earnings Report
Immune Pharmaceuticals, Inc. | 8-K: Current report
Immune Pharmaceuticals, Inc. | 8-K: Current report
Immune Pharmaceuticals, Inc. | 10-Q: Q1 2018 Earnings Report
Immune Pharmaceuticals, Inc. | 8-K: Current report
Immune Pharmaceuticals, Inc. | SC 13G/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities by passive investors and certain institutions (Amendment)
Immune Pharmaceuticals, Inc. | DEF 14A: Definitive proxy statements
Immune Pharmaceuticals, Inc. | 8-K: Current report
Immune Pharmaceuticals, Inc. | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition
Immune Pharmaceuticals, Inc. | 424B4: Prospectus
Immune Pharmaceuticals, Inc. | S-1MEF: A new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S 1
Immune Pharmaceuticals, Inc. | EFFECT: Others
Immune Pharmaceuticals, Inc. | CORRESP: CORRESP
Immune Pharmaceuticals, Inc. | CORRESP: CORRESP
Immune Pharmaceuticals, Inc. | CORRESP: CORRESP
Immune Pharmaceuticals, Inc. | UPLOAD: Others
Immune Pharmaceuticals, Inc. | CORRESP: CORRESP
No Data